- 2016 – New international patent application.
- 2015 – Orphan drug designation for Biliary tract cancer (EMA).
- 2014 – First clinical trial of Redaporfin in head and neck cancer.
- 2012-2013 – Safety pharmacology and toxicology GLP studies.
- 2011-2012 – Nonclinical proof-of-concept studies with Redaporfin for PDT of cancer.
- 2010 – Luzitin set-up. Licensing-in of initial IP from the University of Coimbra.